Neo Ivy Capital Management Purchases Shares of 24,241 Vaxcyte, Inc. $PCVX

Neo Ivy Capital Management acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX) during the 2nd quarter, Holdings Channel reports. The firm acquired 24,241 shares of the company’s stock, valued at approximately $788,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. AlphaQuest LLC purchased a new stake in Vaxcyte during the first quarter valued at approximately $33,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Vaxcyte in the 1st quarter worth $35,000. CWM LLC raised its holdings in Vaxcyte by 197.3% in the 2nd quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after purchasing an additional 1,115 shares during the period. IFP Advisors Inc lifted its position in Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in Vaxcyte by 176.7% during the second quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock valued at $70,000 after purchasing an additional 1,380 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on PCVX. BTIG Research reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Vaxcyte in a research note on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. Cowen reiterated a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 price objective on the stock. Finally, Leerink Partners set a $77.00 target price on shares of Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $97.83.

Vaxcyte Stock Up 0.2%

PCVX opened at $47.78 on Friday. The company has a market capitalization of $6.25 billion, a PE ratio of -9.87 and a beta of 1.07. The firm has a 50-day simple moving average of $41.07 and a two-hundred day simple moving average of $35.90. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $94.76.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 4th. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period in the prior year, the firm posted ($0.83) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.